



Relationship between Circadian Clock Gene Expression and Atrial Fibrillation



Yung-Lung Chen (陳永隆), M.D.

Kaohsiung Chang Gung Memorial Hospital, Taiwan

Korean Heart Rhythm Society

COI Disclosure

Name of First Author: Yung-Lung Chen


The authors have no financial conflicts of interest
to disclose concerning the presentation

Outline

- Background
- Methods
- Results
- Conclusion




Human circadian biologic clock




Circadian timing in our brain and periphery

Suprachiasmatic nuclei (SCN)
: principal circadian oscillator

Local versions of the SCN clockwork are also active **in peripheral**, non-neural tissues, driving the **tissue-specific** cycles of gene expression that underpin circadian organization.




Hypothetical clock mechanism in mammals




Per: Period (1-3)
Clock
Cry: Cryptochrome(1-2)
BMAL1: Brain and muscle ARNT-like protein 1
CK1E: Casein kinase 1E
TIM: Timless
Rev-Erb- α (or NR1D1)
ROR- α: retinoic acid–related orphan receptor


Hypothetical clock mechanism in mammals



Per: Period (1-3)
Clock
Cry: Cryptochrome(1-2)
BMAL1: Brain and muscle ARNT-like protein 1
CK1E: Casein kinase 1E
TIM: Timless
Rev-Erb- α (or NR1D1)
ROR- α: retinoic acid–related orphan receptor

clock-controlled genes expression is also exhibiting daily day–night fluctuation cycles






Circadian Clock Genes and CV disease

- Diurnal variation in cardiovascular events (MI, SCD) → high incidence in morning – mechanism unclear
- *Bmal1* SNP associated with hypertension and T2D (Woon *et al* 2007 PNAS) (Rat and human)
- Clock gene mutants/KO mice display an array of cardiovascular disease e.g. metabolic syndrome, atherosclerosis, BP dysfunction (e.g. Turek *et al* 2005 Science)
- Time-of-day dependence in myocardial I/R tolerance in mice, mediated by the cardiomyocyte-specific clock → in phase with rhythm in MI onset in human (Durgan *et al* 2010 Circ Res)
- ROR α KO mouse models display overt cardiovascular phenotypes (e.g. atherosclerosis, vascular tone dysfunction)



Circadian variation of paroxysmal AF



Circadian Variation of Paroxysmal Atrial Fibrillation.
Yamashita, Takeshi; Murakawa, Yuji; Sezaki, Kazunori; Inoue, Masashi; Hayami, Noriyuki; Shuzui, Yutaka; Omata, Masao
Circulation. 96(5):1537-1541, September 2, 1997.

Figure 1. Hourly total duration of paroxysmal atrial fibrillation accumulated in the total of 150 patients. A single-harmonic fit is represented by a curved line. A prominent circadian rhythm is present, with a peak at midnight and a nadir at 11 AM.

CCGs regulate HRV changes

- Circadian rhythms in **heart rate variability** are driven by an intrinsic mechanism in humans
- Pts with an extended **Per3** tandem repeat exhibit elevated heart rate
- Selective deletion of peroxisome proliferator-activated receptor- γ (PPAR- γ), a putative activator of **BMAL1**, results in diminished heart rate diurnal variations

Clock-controlled genes and arrhythmia

- Gene expression microarray analysis showed **multiple signal transduction** cascade components and **ion channels** as clock-controlled genes
- **Potassium channel** (Kv1.5,Kv4.2) (rat)
- **Gap junction** (Connexin 40,43,45) (rodent and mammalian)

Circulation. 1998;97:686–691.

Dev Genet. 1999;24:82–90.

*Circ Res.*1994;74:839–851.

J Interv Card Electrophysiol. 2000;4:459–467.



Methods


Inclusion: 73 Pts with SSS s/p PPM between 2018/9-2019/12

Exclusion: autoimmune disease, malignancy, and chronic inflammation

Definition of AF and AF type: according to clinical guideline

AHREs (atrial high-rate episodes): atrial rate \geq 180 BPM more than 5 mins

14 CCGs expression by qRT-PCR



PPM: permanent pacemaker

PB: peripheral blood

Figure 1. Flow chart of study design.


Baseline characteristics of the study population

Variables	Persistent AF (n = 15)	Paroxysmal AF (n = 28)	No AF (n = 30)	p-Value
Age	71.0 ± 8.3	71.0 ± 8.1	72.2 ± 8.7	0.840
Sex (Male/Female)	12/3	12/16 ^a	9/21 ^a	0.006
Hypertension	7 (46.7%)	18 (64.3%)	19 (63.3%)	0.481
Diabetes mellitus	6 (40%)	5 (17.9%)	8 (26.7%)	0.287
Previous stroke	3 (20%)	5 (17.9%)	2 (6.7%)	0.338
Heart failure	1 (6.7%)	5 (17.9%)	2 (6.7%)	0.330
Coronary artery disease	3 (20%)	5 (17.9%)	5 (16.7%)	0.963
Chronic kidney disease	3 (20%)	2 (7.1%)	6 (20%)	0.328
Anxiety	4 (26.7%)	8 (28.6%)	7 (23.3%)	0.900
Benzodiazepine	2 (13.3%)	2 (7.1%)	4 (13.3%)	0.713
Non-benzodiazepine	1 (6.7%)	0 (0%)	2 (6.7%)	0.378
Average heart rate	74.5 ± 5.0	73.4 ± 7.9	71.9 ± 5.3	0.488
AHRE burden (IQR)	100 (100–100)	0.5 (0–3.5) ^a	0 (0–0) ^a	<0.001
Echocardiographic data				
Left atrium diameter(mm)	49.3 ± 9.3	40.8 ± 10.2 ^a	38.9 ± 4.4 ^a	<0.001
Left atrial volume (cm ³)	102.7 ± 37.5	62.4 ± 43.8 ^a	50.7 ± 19.2 ^a	<0.001
Aorta (mm)	32.9 ± 5.1	32.1 ± 4.3	32.7 ± 4.4	0.802
LVEDD (mm)	51.1 ± 8.3	47.4 ± 5.6	48.4 ± 8.3	0.294
LVESD (mm)	35.1 ± 9.4	30.4 ± 4.3	30.8 ± 7.5	0.089
LVEF (%)	60.0 ± 10.9	65.1 ± 7.6	65.9 ± 9.2	0.106
Septal E/e' ratio	16.3 ± 9.5	13.9 ± 8.9	14.2 ± 9.3	0.740
DT (ms)	181.2 ± 64.6	224.6 ± 72.7	196.7 ± 44.2	0.097
PAP (mmHg)	25.2 ± 10.8	24.9 ± 9.2	24.7 ± 8.4	0.984

Baseline characteristics of the study population

Variables	Persistent AF (n = 15)	Paroxysmal AF (n = 28)	No AF (n = 30)	p-Value
Age	71.0 ± 8.3	71.0 ± 8.1	72.2 ± 8.7	0.840
Sex (Male/Female)	12/3	12/16 ^a	9/21 ^a	0.006
Hypertension	7 (46.7%)	18 (64.3%)	19 (63.3%)	0.481
Diabetes mellitus	6 (40%)	5 (17.9%)	8 (26.7%)	0.287
Previous stroke	3 (20%)	5 (17.9%)	2 (6.7%)	0.338
Heart failure	1 (6.7%)	5 (17.9%)	2 (6.7%)	0.330
Coronary artery disease	3 (20%)	5 (17.9%)	5 (16.7%)	0.963
Chronic kidney disease	3 (20%)	2 (7.1%)	6 (20%)	0.328
Anxiety	4 (26.7%)	8 (28.6%)	7 (23.3%)	0.900
Benzodiazepine	2 (13.3%)	2 (7.1%)	4 (13.3%)	0.713
Non-benzodiazepine	1 (6.7%)	0 (0%)	2 (6.7%)	0.378
Average heart rate	74.5 ± 5.0	73.4 ± 7.9	71.9 ± 5.3	0.488
AHRE burden (IQR)	100 (100–100)	0.5 (0–3.5) ^a	0 (0–0) ^a	<0.001
Echocardiographic data				
Left atrium diameter(mm)	49.3 ± 9.3	40.8 ± 10.2 ^a	38.9 ± 4.4 ^a	<0.001
Left atrial volume (cm ³)	102.7 ± 37.5	62.4 ± 43.8 ^a	50.7 ± 19.2 ^a	<0.001
Aorta (mm)	32.9 ± 5.1	32.1 ± 4.3	32.7 ± 4.4	0.802
LVEDD (mm)	51.1 ± 8.3	47.4 ± 5.6	48.4 ± 8.3	0.294
LVESD (mm)	35.1 ± 9.4	30.4 ± 4.3	30.8 ± 7.5	0.089
LVEF (%)	60.0 ± 10.9	65.1 ± 7.6	65.9 ± 9.2	0.106
Septal E/e' ratio	16.3 ± 9.5	13.9 ± 8.9	14.2 ± 9.3	0.740
DT (ms)	181.2 ± 64.6	224.6 ± 72.7	196.7 ± 44.2	0.097
PAP (mmHg)	25.2 ± 10.8	24.9 ± 9.2	24.7 ± 8.4	0.984

Expression levels of the 14 CCGs



Linear regression model predicting AHREs burden

$R^2 = 0.633$; $p < 0.001$

Variables	Standardized β Coefficient	p -Value
Male sex	0.188	0.066
Age	0.139	0.127
Left atrial volume	0.608	<0.001
<i>BMAL1</i>	0.385	0.050
<i>CRY1</i>	0.386	0.041
<i>CRY2</i>	-0.528	0.382
<i>NR1D1</i>	1.149	0.016
<i>NR1D2</i>	0.248	0.569
<i>PER2</i>	-0.128	0.687
<i>PER3</i>	0.148	0.371
<i>RORA</i>	-1.676	0.025
<i>RORB</i>	0.257	0.112
<i>RORC</i>	-0.470	0.064
<i>TIM</i>	0.265	0.520

AHREs: atrial high-rate episodes



Hypothesis

The expression of CCGs


- is altered through the change of the light/dark cycle in mice
- influences the gene expression related to energy metabolism 、 inflammation 、 fibrosis and gap junction
- causes the electrical and mechanical remodeling of the mice heart

Outline

- Background
- **Methods**
- Results
- Conclusion




C57BL/6J mice



LD: 12-hr Light/12-hr Dark cycle

RLD (3L4D): 3 days 24hr all-Light, then 4 days 24hr all-Dark

- Sacrificed at 24 weeks: 9 am
 - **Gene:**
 - Metabolism: PPAR α . PGC-1
 - Inflammation: IL-1 β . IL-6. IL-10
 - Fibrosis: Timp1. Smad4. TGF- β 1
 - Gap junction: GJA1
- Anesthesia: Avertin
 - EKG (iWorx-100B+ LabScribe): 5 mins
 - ECHO (Philips)
 - Transesophageal electrical stimulation





Outline





- Background
- Methods
- **Results**
- Conclusion




mRNAs expression of CCGs







mRNA expression of clock-controlled genes



ECG parameters






N: Normal LD
 R: Reverse LD
 mean ± SEM

Transesophageal Electrical Stimulation Study



Burst pacing 30 secs with atrial 1:1 capture till 25 ms

No AF lasting 1 sec was noted



Conclusion

- In our altering light-dark cycle mice model, the expression of CCGs was influenced. (*BMAL1*, *Clock*, *ROR-A*, *ROR-C*, *NR1D1*)
- The expression of clock-controlled genes, including *PPAR α* , *PGC-1 α* , *IL-10* and *TGF- β 1* were also influenced.
- However, the electrical and structural remodeling was not found in our altered light-dark cycle model.



THANKS FOR YOUR ATTENTION



高雄長庚紀念醫院
Kaohsiung Chang Gung Memorial Hospital



KHRS 2023